China biopharma innovation enters 2.0, with global partnership models expanding from licensing to NewCo and strategic collaborations

Overview

The report summarizes the inaugural Morgan Stanley China Biopharma Symposium held in Shanghai on June 17-18, 2026. The event brought together more than 50 Chinese biopharma/biotech companies, more than 20 global pharmaceutical companies, and more than 10 PE/VC investors to discuss how Chinese innovation is connecting with the global biopharmaceutical frontier.

Core views

The core views include four main themes: first, China biopharma innovation is extending from engineering strengths such as ADCs, bispecific antibodies, and GLP-1 into areas including ultra-long-acting delivery, extrahepatic delivery, oral alternative therapies, in vivo gene editing, and cell therapy; second, BD transaction structures are expanding from pure licensing to NewCo, co-co, and strategic partnerships; third, the competitive focus in AI drug discovery is shifting from model platforms to verifiable assets; fourth, Hengrui demonstrates a viable globalization path for Chinese pharma through partnerships such as Kailera, GSK, and Bristol Myers Squibb.

Analysis framework

The report uses a conference-notes-style synthesis, drawing on multiple panel discussions, perspectives from global pharmaceutical companies and PE/VCs, and presentations by Hengrui management to distill industry trends, changes in transaction structures, technology opportunities, and requirements for globalization readiness; it does not disclose a single-company financial forecast model or valuation analysis.

Methodology notes

• Conference notesThematic synthesis method

  Distilling industry changes by conference discussion topics

  The report organizes symposium content into four themes—Innovation 2.0, partnership structures, AI drug discovery, and Hengrui globalization—with a focus on reflecting areas of consensus and divergence among industry participants.

• Industry viewMorgan Stanley industry view framework

  Attractive industry view

  Attractive indicates that analysts expect the industry coverage universe to perform attractively relative to the relevant broad market benchmark over the next 12-18 months.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Chinese biopharma/biotech companies

  Core assets of the industry theme

  Strengths

  They possess engineering capabilities, lower development costs, rapid execution, and gradually strengthening differentiated innovation capabilities.

  Weaknesses

  First-in-class innovation remains at an early stage, and biological risk may not yet be fully priced in.

  Comparison

  Compared with fast-follow and engineering optimization in Innovation 1.0, Innovation 2.0 places greater emphasis on new modalities, new disease areas, and underlying biological differentiation.

  Risks

  Geopolitics, IP risk, clinical data maturity, global translatability, and cross-border structural complexity.

• Hengrui

  A globalization case for Chinese pharmaceutical companies

  Strengths

  It has end-to-end R&D capabilities, a domestic development and commercialization foundation, and the ability to monetize through NewCo, strategic partnerships, and milestones/royalties.

  Weaknesses

  The report does not emphasize company-specific weaknesses, but partnerships still need to resolve target, development, or commercialization-related bottlenecks.

  Comparison

  As one of China's largest biopharma companies, Hengrui is used as a sample for observing the globalization path of leading Chinese pharmaceutical companies.

  Risks

  When partnered assets are in early stages, clinical, regulatory, commercialization, and partner execution risks still need to be monitored.

• AI-driven drug discovery/AIDD companies

  Technology theme and potential source of innovative assets

  Strengths

  They can combine foundation models, robotic labs, and AI antibody design to compress the path from hit identification to lead optimization.

  Weaknesses

  Key bottlenecks include access to proprietary data, especially failed data, as well as deep biological knowledge.

  Comparison

  Companies that vertically integrate AI, automation, translational biology, and proprietary assets have higher barriers than pure model companies lacking asset validation.

  Risks

  Insufficient asset validation, intensifying competition, inadequate data barriers, and unclear commercialization models.

• Global pharmaceutical companies and PE/VCs

  Buyers, partners, and providers of capital for Chinese innovative assets

  Strengths

  Confidence in Chinese discovery platforms and early-stage assets is gradually increasing, driving the rise of NewCo, co-co, and strategic partnerships.

  Weaknesses

  They maintain strict requirements on scientific rationale, data maturity, IP, CMC, and global regulatory transferability.

  Comparison

  Traditional out-licensing remains suitable for clinical-stage assets with clearer development strategies, while earlier-stage assets may be better suited to NewCo or strategic partnerships.

  Risks

  Weak scientific rationale, immature data, complex cross-border structures, and geopolitical uncertainty may become obstacles to transactions.

Key data

• Conference time and locationJune 17-18, 2026, ShanghaiThe report publication date is June 23, 2026.
• Participating Chinese biopharma/biotech companies50+Used to demonstrate the breadth of supply of Chinese innovative assets and platforms.
• Participating global pharmaceutical companies20+Used to observe changing demand from multinational pharma for Chinese assets and platforms.
• Participating PE/VC investors10+Used to reflect capital-market interest in Chinese innovation and transaction structures.
• AIDD process compression caseApproximately 9 monthsThe report states that one AI-driven drug discovery company shortened the process from hit identification to lead generation and optimization to about 9 months.
• Kailera advancement paceCompleted two rounds of private financing within 18 months followed by a NASDAQ IPOHengrui's GLP-1 NewCo case is used to illustrate the flexibility of globalization deal structures for Chinese pharmaceutical companies.

Impact & implications

The investment implication is that focus in the China biopharma sector is upgrading from low cost and execution speed toward globally translatable clinical development, clear IP structures, verifiable differentiated biology, and diversified BD monetization capabilities. Asset-level licensing is viewed as safer than M&A, but only if company structure, IP, and regulatory documentation can withstand due diligence.

Risks

• First-in-class innovation remains at an early stage, and biological risk may not be fully recognized by investors.
• Geopolitics remains a source of uncertainty, especially affecting cross-border partnerships, licensing, and M&A.
• Common transaction obstacles for global pharmaceutical companies include weak scientific rationale, immature data, IP risk, insufficient global translatability, CMC uncertainty, and complex cross-border structures.
• AI-driven drug discovery faces bottlenecks in proprietary data and biological knowledge, and pure model companies lacking asset validation may face more intense competition.
• The report includes disclosures that Morgan Stanley has business relationships, investment banking services, or market-making arrangements with multiple covered companies, and investors should pay attention to potential conflicts of interest.

What to watch

• Whether Chinese innovation continues to expand beyond ADCs, bispecific antibodies, and GLP-1 into more modalities and disease areas.
• Whether NewCo, co-co, and strategic partnerships become more common structures for the globalization of Chinese assets.
• Whether Chinese companies' clinical designs can meet U.S. or global regulatory package requirements, including high-standard control groups, data transferability, and patient diversity.
• Whether asset IP ownership, corporate structure, and cross-border arrangements are sufficiently clear and can pass due diligence.
• Whether AIDD companies can deliver credible in-house assets and clear monetization models, rather than just model-platform narratives.
• Follow-up clinical and capital-markets progress of Hengrui's related partnerships with Kailera, GSK, and Bristol Myers Squibb.